首页 > 最新文献

Translational andrology and urology最新文献

英文 中文
Recurrence of vesico-ureteral reflux in children: is still the endoscopic injection the best option? 儿童膀胱输尿管反流复发:内窥镜注射仍是最佳选择吗?
IF 1.9 3区 医学 Q4 ANDROLOGY Pub Date : 2024-08-31 Epub Date: 2024-08-26 DOI: 10.21037/tau-24-76
Francesca Nascimben, Isabelle Talon, Consuelo Maldonado, Rossella Angotti, Francesco Molinaro, Raphael Moog, Francois Becmeur

Background: Endoscopic injection (EI) is a safe treatment for vesico-ureteral reflux (VUR) in children, but recurrences are not insignificant. This study aims to show if multiple EI is still the best first line management even if in case of recurrences.

Methods: All patients affected by primary VUR, treated with at least one EI and with at least 5 years follow up were included. All general data were analyzed. Recurrence rate after one, two and three EIs were calculated.

Results: One hundred and sixty-one patients (total number =210) were healed after 1 injection, 28 after 2 and 4 after 3 with a global success rate of 91.90%. Recurrence rate is higher in patients older than 3 years old and with IV and V reflux grade. Even if 67.7% of recurrent VUR after one injection was symptomatic, diagnosis of recurrences after multiple EI was mainly radiological. Only 8% of the patients underwent EI need an anti-reflux surgery.

Conclusions: Thanks to its low costs and the acceptable recurrence rate, Deflux EI should be proposed as the first therapeutic approach for children affected by VUR, especially in those with low and moderate grades of VUR. Multiple injections could be contraindicated only in older children thank 1 year with high-grade VUR (IV symptomatic and V grade).

背景:内镜注射(EI)是治疗儿童膀胱输尿管反流(VUR)的一种安全方法,但复发率并不低。本研究旨在说明,即使出现复发,多次内镜注射是否仍是最佳的一线治疗方法:方法:纳入所有接受过至少一次 EI 治疗且随访至少 5 年的原发性 VUR 患者。对所有一般数据进行分析。结果:共有 161 名患者(总人数)接受了 EI 治疗:161 名患者(总人数 = 210)在注射 1 次后痊愈,28 人在注射 2 次后痊愈,4 人在注射 3 次后痊愈,总体成功率为 91.90%。3 岁以上、IV 级和 V 级反流的患者复发率较高。即使 67.7% 注射一次后复发的 VUR 是无症状的,但多次 EI 后复发的诊断主要是放射学诊断。只有 8% 接受过 EI 的患者需要进行抗反流手术:结论:由于费用低廉且复发率可接受,应建议将脱流 EI 作为治疗 VUR 患儿的首选方法,尤其是低度和中度 VUR 患儿。只有年龄大于 1 岁、患有高级别 VUR(IV 级无症状和 V 级)的儿童才禁忌多次注射。
{"title":"Recurrence of vesico-ureteral reflux in children: is still the endoscopic injection the best option?","authors":"Francesca Nascimben, Isabelle Talon, Consuelo Maldonado, Rossella Angotti, Francesco Molinaro, Raphael Moog, Francois Becmeur","doi":"10.21037/tau-24-76","DOIUrl":"https://doi.org/10.21037/tau-24-76","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic injection (EI) is a safe treatment for vesico-ureteral reflux (VUR) in children, but recurrences are not insignificant. This study aims to show if multiple EI is still the best first line management even if in case of recurrences.</p><p><strong>Methods: </strong>All patients affected by primary VUR, treated with at least one EI and with at least 5 years follow up were included. All general data were analyzed. Recurrence rate after one, two and three EIs were calculated.</p><p><strong>Results: </strong>One hundred and sixty-one patients (total number =210) were healed after 1 injection, 28 after 2 and 4 after 3 with a global success rate of 91.90%. Recurrence rate is higher in patients older than 3 years old and with IV and V reflux grade. Even if 67.7% of recurrent VUR after one injection was symptomatic, diagnosis of recurrences after multiple EI was mainly radiological. Only 8% of the patients underwent EI need an anti-reflux surgery.</p><p><strong>Conclusions: </strong>Thanks to its low costs and the acceptable recurrence rate, Deflux EI should be proposed as the first therapeutic approach for children affected by VUR, especially in those with low and moderate grades of VUR. Multiple injections could be contraindicated only in older children thank 1 year with high-grade VUR (IV symptomatic and V grade).</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 8","pages":"1446-1454"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urologist's role on smoking cessation counseling in patients presenting with asymptomatic hematuria: single academic institution experience. 泌尿科医生在无症状血尿患者戒烟咨询中的作用:单个学术机构的经验。
IF 1.9 3区 医学 Q4 ANDROLOGY Pub Date : 2024-08-31 Epub Date: 2024-08-26 DOI: 10.21037/tau-23-592
Fumihiko Nakamura, Lauren Tranthem, Thomas Barefoot, Sarah Johnson, Michael Goedde, Kellen Choi

Background: Bladder cancer is known to be strongly associated with smoking tobacco products. Urologists thus have an imperative role in providing smoking cessation counseling to patients to prevent the development of bladder cancer, recurrence, and other morbidities associated with smoking. Asymptomatic hematuria is often a presenting clinical symptom that warrants further investigation. This study aims to determine if smokers who have an episode of asymptomatic hematuria are more likely to quit smoking if urologists counsel them on formal smoking cessation.

Methods: We completed a retrospective chart review of patients who presented for asymptomatic hematuria at our institution between January 2017 and March 2020. A total of 435 patients were identified, 134 of which were active smokers at the presentation time. We recorded smoking status at initial presentation, documentation of smoking cessation counseling, and smoking status at one year follow-up. Fischer's exact test was used for analysis. Statistical significance was set by convention at P<0.05.

Results: The percentage of patients presenting with an episode of asymptomatic hematuria that quit or cut back at one year follow-up was 24.2% [95% confidence interval (CI): 13.8%, 34.7%]. In assessing the effect of formal smoking cessation counseling, 33.3% of patients with documented smoking cessation counseling quit or cut back at one year, compared to 22.8% of patients with no documented counseling. However, these findings were not statistically significant (P=0.68). Of note, smoking cessation counseling was recorded in 19 active smokers (14.2%), and 68 active smokers (50.7%) did not receive follow-up at one year.

Conclusions: Smoking cessation remains a challenging endeavor for both patients and urologists. Formal counseling did not significantly contribute to quitting rates among patients, and rates of documented counseling from providers were unsubstantial. Urologists should use hematuria work-up visits as an opportunity to counsel patients on smoking cessation.

背景:众所周知,膀胱癌与吸烟密切相关。因此,泌尿科医生必须为患者提供戒烟咨询,以预防膀胱癌的发生、复发以及其他与吸烟相关的疾病。无症状血尿通常是值得进一步研究的临床症状。本研究旨在确定,如果泌尿科医生对出现无症状血尿的吸烟者进行正规戒烟指导,他们是否更有可能戒烟:我们对2017年1月至2020年3月期间在我院就诊的无症状血尿患者进行了回顾性病历审查。共确定了 435 名患者,其中 134 名患者在就诊时是活跃的吸烟者。我们记录了患者初次就诊时的吸烟情况、戒烟咨询记录以及随访一年时的吸烟情况。分析采用费舍尔精确检验。统计显著性按惯例设定为 PResults:无症状血尿患者在随访一年后戒烟或减少吸烟的比例为 24.2% [95%置信区间 (CI):13.8%, 34.7%]。在评估正规戒烟咨询的效果时,有戒烟咨询记录的患者在一年后戒烟或减少吸烟的比例为 33.3%,而没有戒烟咨询记录的患者为 22.8%。不过,这些结果并无统计学意义(P=0.68)。值得注意的是,19 名活跃吸烟者(14.2%)接受了戒烟咨询,68 名活跃吸烟者(50.7%)一年后未接受随访:对于患者和泌尿科医生来说,戒烟仍然是一项具有挑战性的工作。正式的戒烟咨询对患者的戒烟率没有明显的促进作用,医疗服务提供者提供的有记录的戒烟咨询率也不高。泌尿科医生应利用血尿检查的机会为患者提供戒烟咨询。
{"title":"Urologist's role on smoking cessation counseling in patients presenting with asymptomatic hematuria: single academic institution experience.","authors":"Fumihiko Nakamura, Lauren Tranthem, Thomas Barefoot, Sarah Johnson, Michael Goedde, Kellen Choi","doi":"10.21037/tau-23-592","DOIUrl":"https://doi.org/10.21037/tau-23-592","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer is known to be strongly associated with smoking tobacco products. Urologists thus have an imperative role in providing smoking cessation counseling to patients to prevent the development of bladder cancer, recurrence, and other morbidities associated with smoking. Asymptomatic hematuria is often a presenting clinical symptom that warrants further investigation. This study aims to determine if smokers who have an episode of asymptomatic hematuria are more likely to quit smoking if urologists counsel them on formal smoking cessation.</p><p><strong>Methods: </strong>We completed a retrospective chart review of patients who presented for asymptomatic hematuria at our institution between January 2017 and March 2020. A total of 435 patients were identified, 134 of which were active smokers at the presentation time. We recorded smoking status at initial presentation, documentation of smoking cessation counseling, and smoking status at one year follow-up. Fischer's exact test was used for analysis. Statistical significance was set by convention at P<0.05.</p><p><strong>Results: </strong>The percentage of patients presenting with an episode of asymptomatic hematuria that quit or cut back at one year follow-up was 24.2% [95% confidence interval (CI): 13.8%, 34.7%]. In assessing the effect of formal smoking cessation counseling, 33.3% of patients with documented smoking cessation counseling quit or cut back at one year, compared to 22.8% of patients with no documented counseling. However, these findings were not statistically significant (P=0.68). Of note, smoking cessation counseling was recorded in 19 active smokers (14.2%), and 68 active smokers (50.7%) did not receive follow-up at one year.</p><p><strong>Conclusions: </strong>Smoking cessation remains a challenging endeavor for both patients and urologists. Formal counseling did not significantly contribute to quitting rates among patients, and rates of documented counseling from providers were unsubstantial. Urologists should use hematuria work-up visits as an opportunity to counsel patients on smoking cessation.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 8","pages":"1372-1377"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer? 原发肿瘤是否适合在生物标记物指导下治疗转移性尿路癌?
IF 1.9 3区 医学 Q4 ANDROLOGY Pub Date : 2024-08-31 Epub Date: 2024-08-26 DOI: 10.21037/tau-24-112
Mathijs P Scholtes, Geert J L H van Leenders, Debbie G J Robbrecht, Joost L Boormans, Tahlita C M Zuiverloon
{"title":"Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?","authors":"Mathijs P Scholtes, Geert J L H van Leenders, Debbie G J Robbrecht, Joost L Boormans, Tahlita C M Zuiverloon","doi":"10.21037/tau-24-112","DOIUrl":"https://doi.org/10.21037/tau-24-112","url":null,"abstract":"","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 8","pages":"1341-1345"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Construction and validation of a prediction model for inguinal lymph node metastasis of penile malignancy. 阴茎恶性肿瘤腹股沟淋巴结转移预测模型的构建与验证
IF 1.9 3区 医学 Q4 ANDROLOGY Pub Date : 2024-08-31 Epub Date: 2024-08-26 DOI: 10.21037/tau-24-145
Kun Zhang, Longguo Dai, Huijian Wang, Shiyi Xu, Xianli Cheng, Yang Wang, Haiyang Jiang, Chongjian Zhang, Bingyu Zhu, Yuanlong Shi, Yu Bai

Background: Penile squamous cell carcinoma is a relatively rare malignancy among male malignancies, there are more than 30,000 new cases and more than 10,000 deaths of penile cancer annually. In patients with penile malignancy, inguinal lymph node metastasis (ILNM) significantly reduces patient survival. Thus, we identified the risk factors for ILNM in penile malignancies, aiming to develop a precise prediction model.

Methods: We retrospectively analyzed 112 male patients with penile cancer. All subjects underwent penile surgery and inguinal lymphadenectomy at the same time, and postoperative pathology confirmed ILNM. Fisher's exact test, t-test, and Wilcoxon rank sum test were used to assess differences in demographic information and clinical features between the two groups, followed by logical least absolute shrinkage and selection operator (LASSO) regression analysis to determine risk factors of ILNM. The prediction model was constructed using nomogram.

Results: LASSO regression revealed that age [β=-0.005, odds ratio (OR) =0.995], smoking history (β=-0.006, OR =0.994) and interleukin 2 (IL-2) level (β=-0.0112, OR =0.989) were protective against ILNM. However, lymph node diameter (β=0.3117, OR =1.366), T-stage (β=0.1254, OR =1.134), fibrinogen (β=0.0377, OR =1.038), IL-4 level (β=0.004, OR =1.001), and neutrophil-to-lymphocyte ratio (β=0.0355, OR =1.034) were risk factors for developing ILNM. When assessing the risk of metastasis, it is crucial to balance these factors. The aforementioned characteristics were utilized to establish the predictive model, which demonstrated a good predictive ability with an area under the curve (AUC) value of 0.81. Moreover, internal leave-one-way cross-validation was used to construct a nomogram showing consistency, with an AUC of 0.75.

Conclusions: The diagnosis of ILNM in penile malignant tumors can be predicted through clinicopathological features, biochemical tests, and prediction models based on tumor markers.

背景:阴茎鳞状细胞癌是男性恶性肿瘤中较为罕见的恶性肿瘤,每年新发病例超过 30,000 例,死亡人数超过 10,000 例。在阴茎恶性肿瘤患者中,腹股沟淋巴结转移(ILNM)会显著降低患者的生存率。因此,我们确定了阴茎恶性肿瘤腹股沟淋巴结转移的风险因素,旨在建立一个精确的预测模型:我们对112例男性阴茎癌患者进行了回顾性分析。所有受试者均同时接受了阴茎手术和腹股沟淋巴结切除术,术后病理证实为ILNM。采用费舍尔精确检验、t检验和Wilcoxon秩和检验评估两组患者在人口统计学信息和临床特征方面的差异,然后采用逻辑最小绝对缩小和选择算子(LASSO)回归分析确定ILNM的风险因素。预测模型采用提名图构建:LASSO回归结果显示,年龄[β=-0.005,几率比(OR)=0.995]、吸烟史(β=-0.006,OR=0.994)和白细胞介素2(IL-2)水平(β=-0.0112,OR=0.989)对ILNM有保护作用。然而,淋巴结直径(β=0.3117,OR =1.366)、T 分期(β=0.1254,OR =1.134)、纤维蛋白原(β=0.0377,OR =1.038)、IL-4 水平(β=0.004,OR =1.001)和中性粒细胞与淋巴细胞比率(β=0.0355,OR =1.034)是发生 ILNM 的风险因素。在评估转移风险时,平衡这些因素至关重要。利用上述特征建立的预测模型显示出良好的预测能力,其曲线下面积(AUC)值为 0.81。此外,利用内部单向交叉验证构建的提名图显示出一致性,AUC 为 0.75:结论:通过临床病理特征、生化检验和基于肿瘤标志物的预测模型,可以预测阴茎恶性肿瘤中ILNM的诊断。
{"title":"Construction and validation of a prediction model for inguinal lymph node metastasis of penile malignancy.","authors":"Kun Zhang, Longguo Dai, Huijian Wang, Shiyi Xu, Xianli Cheng, Yang Wang, Haiyang Jiang, Chongjian Zhang, Bingyu Zhu, Yuanlong Shi, Yu Bai","doi":"10.21037/tau-24-145","DOIUrl":"https://doi.org/10.21037/tau-24-145","url":null,"abstract":"<p><strong>Background: </strong>Penile squamous cell carcinoma is a relatively rare malignancy among male malignancies, there are more than 30,000 new cases and more than 10,000 deaths of penile cancer annually. In patients with penile malignancy, inguinal lymph node metastasis (ILNM) significantly reduces patient survival. Thus, we identified the risk factors for ILNM in penile malignancies, aiming to develop a precise prediction model.</p><p><strong>Methods: </strong>We retrospectively analyzed 112 male patients with penile cancer. All subjects underwent penile surgery and inguinal lymphadenectomy at the same time, and postoperative pathology confirmed ILNM. Fisher's exact test, <i>t</i>-test, and Wilcoxon rank sum test were used to assess differences in demographic information and clinical features between the two groups, followed by logical least absolute shrinkage and selection operator (LASSO) regression analysis to determine risk factors of ILNM. The prediction model was constructed using nomogram.</p><p><strong>Results: </strong>LASSO regression revealed that age [β=-0.005, odds ratio (OR) =0.995], smoking history (β=-0.006, OR =0.994) and interleukin 2 (IL-2) level (β=-0.0112, OR =0.989) were protective against ILNM. However, lymph node diameter (β=0.3117, OR =1.366), T-stage (β=0.1254, OR =1.134), fibrinogen (β=0.0377, OR =1.038), IL-4 level (β=0.004, OR =1.001), and neutrophil-to-lymphocyte ratio (β=0.0355, OR =1.034) were risk factors for developing ILNM. When assessing the risk of metastasis, it is crucial to balance these factors. The aforementioned characteristics were utilized to establish the predictive model, which demonstrated a good predictive ability with an area under the curve (AUC) value of 0.81. Moreover, internal leave-one-way cross-validation was used to construct a nomogram showing consistency, with an AUC of 0.75.</p><p><strong>Conclusions: </strong>The diagnosis of ILNM in penile malignant tumors can be predicted through clinicopathological features, biochemical tests, and prediction models based on tumor markers.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 8","pages":"1436-1445"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methylenetetrahydrofolate reductase (MTHFR) polymorphisms in andrology-a narrative review. 亚甲基四氢叶酸还原酶(MTHFR)多态性与肾病的关系--综述。
IF 1.9 3区 医学 Q4 ANDROLOGY Pub Date : 2024-08-31 Epub Date: 2024-08-23 DOI: 10.21037/tau-24-153
Zisong Xie, Kaifeng Liu, Shengmin Zhang, Yongzhan Gong, Zihao Wang, Pengjie Lu

Background and objective: Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme involved in folate metabolism and one-carbon metabolism. MTHFR gene polymorphism affects enzyme activity. MTHFR gene polymorphism is closely related to many human diseases, such as cardiocerebrovascular diseases, diabetes, neural tube defects (NTDs), tumors, and so on. In the field of Andrology, MTHFR gene polymorphism may be associated with male infertility and erectile dysfunction (ED), and there is a possibility of treating male infertility and ED by supplementing with folic acid. However, its exact pathophysiologic mechanism is not fully understood. We sought to obtain a robust understanding of the interactions between MTHFR gene polymorphism, oxidative stress, DNA methylation, hyperhomocysteinemia (HHcy), male infertility, and ED.

Methods: We performed a non-systematic literature review using the PubMed database to identify articles specifically related to MTHFR, male infertility and ED.

Key content and findings: Our literature review on MTHFR gene polymorphism in male infertility patients indicates a significant association between C677T gene polymorphism and male infertility. There is limited literature on the correlation between ED and MTHFR gene polymorphism, and there are two different conclusions, related and unrelated. More clinical data are needed to clarify the conclusion. There is a possibility of using folic acid supplementation to treat male infertility and ED, especially for patients with thymine-thymine (TT) genotype. Future research is necessary to further understand the relationship between MTHFR gene polymorphism and male infertility and ED.

Conclusions: Our literature review on MTHFR gene polymorphism in male infertility patients indicates a significant association between C677T gene polymorphism and male infertility. Folic acid supplementation can improve sperm quality. The correlation between MTHFR gene polymorphisms and ED is questionable and needs to be confirmed by more clinical data. MTHFR gene polymorphisms are associated with homocysteine (Hcy) levels, which affects vascular endothelial function and may be related to the development of vascular ED (VED). Folic acid supplementation improves International Index for Erectile Function (IIEF) questionnaire scores in ED patients in whom phosphodiesterase 5 inhibitor (PDE5i) alone is ineffective.

背景和目的:亚甲基四氢叶酸还原酶(MTHFR)是参与叶酸代谢和一碳代谢的关键酶。MTHFR 基因多态性会影响酶的活性。MTHFR 基因多态性与心脑血管疾病、糖尿病、神经管缺陷(NTD)、肿瘤等多种人类疾病密切相关。在 Andrology 领域,MTHFR 基因多态性可能与男性不育和勃起功能障碍(ED)有关,因此有可能通过补充叶酸来治疗男性不育和 ED。然而,其确切的病理生理机制尚不完全清楚。我们试图深入了解 MTHFR 基因多态性、氧化应激、DNA 甲基化、高同型半胱氨酸血症(HHcy)、男性不育症和 ED 之间的相互作用:我们利用PubMed数据库进行了一次非系统性文献综述,以确定与MTHFR、男性不育和ED具体相关的文章:我们对男性不育患者MTHFR基因多态性的文献综述表明,C677T基因多态性与男性不育之间存在显著关联。关于ED与MTHFR基因多态性之间相关性的文献有限,存在相关和不相关两种不同的结论。需要更多的临床数据来明确结论。有可能使用叶酸补充剂来治疗男性不育和 ED,尤其是胸腺嘧啶-胸腺嘧啶(TT)基因型患者。未来的研究有必要进一步了解MTHFR基因多态性与男性不育和ED之间的关系:我们对男性不育患者 MTHFR 基因多态性的文献综述表明,C677T 基因多态性与男性不育之间存在显著关联。补充叶酸可提高精子质量。MTHFR基因多态性与ED之间的相关性尚存疑问,需要更多临床数据来证实。MTHFR 基因多态性与同型半胱氨酸(Hcy)水平有关,Hcy 会影响血管内皮功能,可能与血管性 ED(VED)的发生有关。补充叶酸可改善仅服用磷酸二酯酶 5 抑制剂(PDE5i)无效的 ED 患者的国际勃起功能指数(IIEF)问卷评分。
{"title":"Methylenetetrahydrofolate reductase (MTHFR) polymorphisms in andrology-a narrative review.","authors":"Zisong Xie, Kaifeng Liu, Shengmin Zhang, Yongzhan Gong, Zihao Wang, Pengjie Lu","doi":"10.21037/tau-24-153","DOIUrl":"https://doi.org/10.21037/tau-24-153","url":null,"abstract":"<p><strong>Background and objective: </strong>Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme involved in folate metabolism and one-carbon metabolism. MTHFR gene polymorphism affects enzyme activity. MTHFR gene polymorphism is closely related to many human diseases, such as cardiocerebrovascular diseases, diabetes, neural tube defects (NTDs), tumors, and so on. In the field of Andrology, MTHFR gene polymorphism may be associated with male infertility and erectile dysfunction (ED), and there is a possibility of treating male infertility and ED by supplementing with folic acid. However, its exact pathophysiologic mechanism is not fully understood. We sought to obtain a robust understanding of the interactions between MTHFR gene polymorphism, oxidative stress, DNA methylation, hyperhomocysteinemia (HHcy), male infertility, and ED.</p><p><strong>Methods: </strong>We performed a non-systematic literature review using the PubMed database to identify articles specifically related to MTHFR, male infertility and ED.</p><p><strong>Key content and findings: </strong>Our literature review on MTHFR gene polymorphism in male infertility patients indicates a significant association between C677T gene polymorphism and male infertility. There is limited literature on the correlation between ED and MTHFR gene polymorphism, and there are two different conclusions, related and unrelated. More clinical data are needed to clarify the conclusion. There is a possibility of using folic acid supplementation to treat male infertility and ED, especially for patients with thymine-thymine (TT) genotype. Future research is necessary to further understand the relationship between MTHFR gene polymorphism and male infertility and ED.</p><p><strong>Conclusions: </strong>Our literature review on MTHFR gene polymorphism in male infertility patients indicates a significant association between C677T gene polymorphism and male infertility. Folic acid supplementation can improve sperm quality. The correlation between MTHFR gene polymorphisms and ED is questionable and needs to be confirmed by more clinical data. MTHFR gene polymorphisms are associated with homocysteine (Hcy) levels, which affects vascular endothelial function and may be related to the development of vascular ED (VED). Folic acid supplementation improves International Index for Erectile Function (IIEF) questionnaire scores in ED patients in whom phosphodiesterase 5 inhibitor (PDE5i) alone is ineffective.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 8","pages":"1592-1601"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data. 基于扩展随访数据结果的晚期肾细胞癌一线治疗的最佳选择。
IF 1.9 3区 医学 Q4 ANDROLOGY Pub Date : 2024-08-31 Epub Date: 2024-08-12 DOI: 10.21037/tau-24-172
Goshi Kitano, Takahiro Kojima
{"title":"Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data.","authors":"Goshi Kitano, Takahiro Kojima","doi":"10.21037/tau-24-172","DOIUrl":"https://doi.org/10.21037/tau-24-172","url":null,"abstract":"","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 8","pages":"1336-1340"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The diagnostic accuracy of urinary neutrophil gelatinase-associated lipocalin in assessing kidney function in severe hydronephrosis. 尿液中性粒细胞明胶酶相关脂联素在评估严重肾积水肾功能方面的诊断准确性。
IF 1.9 3区 医学 Q4 ANDROLOGY Pub Date : 2024-08-31 Epub Date: 2024-08-26 DOI: 10.21037/tau-24-336
Langlang Yang, Longfei Wu, Jinxian Pu, Guglielmo Mantica, Qilin Xi, Feng Li

Background: Up to now, there is no perfect indicator to evaluate the renal function of severe hydronephrosis, which poses difficulties in the selection of clinical treatment decisions. This study investigates the role of neutrophil gelatinase-associated lipocalin (NGAL) in urine drained from the nephrostomy tube shortly after nephrostomy to evaluate the renal function of patients with severe hydronephrosis caused by ureteral obstruction.

Methods: The clinical data, and blood and urine samples of 24 patients with severe hydronephrosis due to ureteral obstruction were retrospectively collected. The NGAL in the urine drained from the nephrostomy tube on the morning of the first day after the procedure was measured. The glomerular filtration rate (GFR) was determined using a nuclear scan, and the clearance rate of creatinine was calculated based on nephrostomy drainage. The correlation between the NGAL level, urine volume post-nephrostomy, affected side GFR, and creatinine clearance rate (Ccr) was assessed. Moreover, the relationship between the urinary NGAL levels and prognosis was analyzed based on whether the patients underwent nephrectomy.

Results: There was a significant correlation between the urine NGAL from the nephrostomy of the affected side and the Ccr and urine volume post-nephrostomy (both P<0.05). Compared with the patients in the kidney preservation group, those who underwent nephrectomy had significantly increased NGAL levels, and significantly reduced Ccrs and nephrostomy drainage urine output. Through the receiver operating characteristic (ROC) curve evaluation, the efficacy of NGAL in predicting nephrectomy was found to be superior to both the Ccr and urine output, with an area under the curve (AUC) of 0.845.

Conclusions: The NGAL in the urine shortly after nephrostomy may indicate severe renal functional deterioration.

背景:到目前为止,还没有一个完美的指标来评估严重肾积水的肾功能,这给临床治疗决策的选择带来了困难。本研究探讨了肾造瘘术后不久从肾造瘘管排出的尿液中嗜中性粒细胞明胶酶相关脂联素(NGAL)在评价输尿管梗阻所致重度肾积水患者肾功能方面的作用:方法:回顾性收集了24例输尿管梗阻导致严重肾积水患者的临床资料、血液和尿液样本。测量术后第一天早晨从肾造瘘管排出的尿液中的 NGAL。通过核素扫描确定肾小球滤过率(GFR),并根据肾造口术引流液计算肌酐清除率。评估了 NGAL 水平、肾造口术后尿量、患侧 GFR 和肌酐清除率(Ccr)之间的相关性。此外,还根据患者是否接受肾切除术分析了尿液 NGAL 水平与预后之间的关系:结果:患侧肾切除术后尿液中的 NGAL 与 Ccr 和肾切除术后尿量(均为 PConclusions)之间存在明显相关性:肾切除术后不久尿液中的NGAL可能预示着严重的肾功能恶化。
{"title":"The diagnostic accuracy of urinary neutrophil gelatinase-associated lipocalin in assessing kidney function in severe hydronephrosis.","authors":"Langlang Yang, Longfei Wu, Jinxian Pu, Guglielmo Mantica, Qilin Xi, Feng Li","doi":"10.21037/tau-24-336","DOIUrl":"https://doi.org/10.21037/tau-24-336","url":null,"abstract":"<p><strong>Background: </strong>Up to now, there is no perfect indicator to evaluate the renal function of severe hydronephrosis, which poses difficulties in the selection of clinical treatment decisions. This study investigates the role of neutrophil gelatinase-associated lipocalin (NGAL) in urine drained from the nephrostomy tube shortly after nephrostomy to evaluate the renal function of patients with severe hydronephrosis caused by ureteral obstruction.</p><p><strong>Methods: </strong>The clinical data, and blood and urine samples of 24 patients with severe hydronephrosis due to ureteral obstruction were retrospectively collected. The NGAL in the urine drained from the nephrostomy tube on the morning of the first day after the procedure was measured. The glomerular filtration rate (GFR) was determined using a nuclear scan, and the clearance rate of creatinine was calculated based on nephrostomy drainage. The correlation between the NGAL level, urine volume post-nephrostomy, affected side GFR, and creatinine clearance rate (Ccr) was assessed. Moreover, the relationship between the urinary NGAL levels and prognosis was analyzed based on whether the patients underwent nephrectomy.</p><p><strong>Results: </strong>There was a significant correlation between the urine NGAL from the nephrostomy of the affected side and the Ccr and urine volume post-nephrostomy (both P<0.05). Compared with the patients in the kidney preservation group, those who underwent nephrectomy had significantly increased NGAL levels, and significantly reduced Ccrs and nephrostomy drainage urine output. Through the receiver operating characteristic (ROC) curve evaluation, the efficacy of NGAL in predicting nephrectomy was found to be superior to both the Ccr and urine output, with an area under the curve (AUC) of 0.845.</p><p><strong>Conclusions: </strong>The NGAL in the urine shortly after nephrostomy may indicate severe renal functional deterioration.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 8","pages":"1555-1565"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A global, propensity-score matched analysis of patients receiving inflatable penile prostheses and the risk of complications, infections, and re-interventions. 对接受充气式阴茎假体的患者以及并发症、感染和再次干预的风险进行全球倾向得分匹配分析。
IF 1.9 3区 医学 Q4 ANDROLOGY Pub Date : 2024-08-31 Epub Date: 2024-08-26 DOI: 10.21037/tau-23-412
Halle E Foss, Zachary J Prebay, David Ebbott, Matthew B Buck, Michael Li, Paul H Chung

Background: Over 25,000 men undergo inflatable penile prosthesis (IPP) placement yearly to treat erectile dysfunction (ED). Although various comorbidities are hypothesized risk factors for complications, this remains incompletely understood. Our objective was to utilize multi-institutional data to characterize risk for reintervention, complications, and infections in patients with common suspected risk factors undergoing IPP placement.

Methods: We queried the TriNetX database for adult men who underwent IPP placement from 2003-2023 utilizing Current Procedural Terminology (CPT) codes. We examined the impact of diabetes mellitus (DM), hypertension (HTN), nicotine use, radiation therapy (RT), radical prostatectomy (RP), and urethral surgery [urethroplasty, artificial urinary sphincter (AUS), male urethral sling (MS)] on clinical outcomes defined by International Classification of Diseases 10th Revision (ICD-10) codes. Our primary outcome was need for reintervention based on CPT codes. Secondary outcomes included overall rates of complication and infection utilizing ICD-10 codes. Analytics were performed using TriNetX to calculate risk ratios (RRs) and Kaplan-Meier (KM) survival. We evaluated outcomes overall and for each individual comparison cohort using the remaining demographic variables to perform propensity score matching (PSM).

Results: In a total of 11,026 patients there was an overall 13.5% risk of undergoing at least one reintervention, with some undergoing multiple based on CPT codes. KM analysis showed a median IPP survival of 18.2 years and a projected 10- and 20-year survival probability at 70.6% and 48.4% respectively. Overall complication rate was 19.3% with a 5.2% rate of infection based on ICD codes. Patients with history of urethral surgery were at higher risk of both IPP complication and re-intervention. When further analyzing type of re-intervention, patients with a history of smoking, prior RP, and prior AUS/MS placement had higher rates of device removal. Patients with a history of diabetes were less likely to undergo IPP replacement at the time of explant. There were no identified risk factors for IPP infection.

Conclusions: This is the largest cohort of patients ever evaluated and can help guide patient selection and counseling. There was a higher rate of IPP complications than previously reported, but this may be due to different reporting parameters. History of prior urethral surgery conferred a higher risk of complications and re-intervention. These results can help guide patient selection and counseling.

背景:每年有超过 25,000 名男性接受充气阴茎假体(IPP)置入术,以治疗勃起功能障碍(ED)。虽然各种合并症被认为是并发症的风险因素,但人们对这一问题的了解仍不全面。我们的目标是利用多机构的数据来描述接受 IPP 置入术的具有常见疑似风险因素的患者的再介入、并发症和感染风险:我们利用当前程序术语 (CPT) 代码查询了 TriNetX 数据库中 2003-2023 年期间接受 IPP 置入手术的成年男性患者。我们研究了糖尿病 (DM)、高血压 (HTN)、尼古丁使用、放射治疗 (RT)、根治性前列腺切除术 (RP) 和尿道手术 [尿道成形术、人工尿道括约肌 (AUS)、男性尿道吊带 (MS)]对国际疾病分类第十次修订版 (ICD-10) 所定义的临床结果的影响。我们的主要结果是根据 CPT 编码确定是否需要再次介入治疗。次要结果包括使用 ICD-10 编码的并发症和感染总发生率。使用 TriNetX 进行分析,计算风险比 (RR) 和 Kaplan-Meier (KM) 存活率。我们使用其余人口统计学变量对总体结果和每个对比队列的结果进行了评估,以进行倾向得分匹配(PSM):共有 11,026 名患者接受了至少一次再介入治疗,总体风险为 13.5%,其中一些患者根据 CPT 编码接受了多次再介入治疗。KM分析显示,IPP的中位生存期为18.2年,预计10年和20年的生存概率分别为70.6%和48.4%。根据 ICD 编码,总体并发症发生率为 19.3%,感染率为 5.2%。有尿道手术史的患者发生 IPP 并发症和再次介入的风险较高。在进一步分析再次介入的类型时,有吸烟史、曾接受过 RP 和曾置入 AUS/MS 的患者的装置移除率较高。有糖尿病史的患者在器械取出时接受 IPP 更换的可能性较低。没有发现IPP感染的风险因素:这是迄今为止评估的最大一批患者,有助于指导患者的选择和咨询。IPP并发症的发生率高于之前的报告,但这可能是由于报告参数不同造成的。既往尿道手术史会增加并发症和再次介入的风险。这些结果有助于指导患者的选择和咨询。
{"title":"A global, propensity-score matched analysis of patients receiving inflatable penile prostheses and the risk of complications, infections, and re-interventions.","authors":"Halle E Foss, Zachary J Prebay, David Ebbott, Matthew B Buck, Michael Li, Paul H Chung","doi":"10.21037/tau-23-412","DOIUrl":"https://doi.org/10.21037/tau-23-412","url":null,"abstract":"<p><strong>Background: </strong>Over 25,000 men undergo inflatable penile prosthesis (IPP) placement yearly to treat erectile dysfunction (ED). Although various comorbidities are hypothesized risk factors for complications, this remains incompletely understood. Our objective was to utilize multi-institutional data to characterize risk for reintervention, complications, and infections in patients with common suspected risk factors undergoing IPP placement.</p><p><strong>Methods: </strong>We queried the TriNetX database for adult men who underwent IPP placement from 2003-2023 utilizing Current Procedural Terminology (CPT) codes. We examined the impact of diabetes mellitus (DM), hypertension (HTN), nicotine use, radiation therapy (RT), radical prostatectomy (RP), and urethral surgery [urethroplasty, artificial urinary sphincter (AUS), male urethral sling (MS)] on clinical outcomes defined by International Classification of Diseases 10th Revision (ICD-10) codes. Our primary outcome was need for reintervention based on CPT codes. Secondary outcomes included overall rates of complication and infection utilizing ICD-10 codes. Analytics were performed using TriNetX to calculate risk ratios (RRs) and Kaplan-Meier (KM) survival. We evaluated outcomes overall and for each individual comparison cohort using the remaining demographic variables to perform propensity score matching (PSM).</p><p><strong>Results: </strong>In a total of 11,026 patients there was an overall 13.5% risk of undergoing at least one reintervention, with some undergoing multiple based on CPT codes. KM analysis showed a median IPP survival of 18.2 years and a projected 10- and 20-year survival probability at 70.6% and 48.4% respectively. Overall complication rate was 19.3% with a 5.2% rate of infection based on ICD codes. Patients with history of urethral surgery were at higher risk of both IPP complication and re-intervention. When further analyzing type of re-intervention, patients with a history of smoking, prior RP, and prior AUS/MS placement had higher rates of device removal. Patients with a history of diabetes were less likely to undergo IPP replacement at the time of explant. There were no identified risk factors for IPP infection.</p><p><strong>Conclusions: </strong>This is the largest cohort of patients ever evaluated and can help guide patient selection and counseling. There was a higher rate of IPP complications than previously reported, but this may be due to different reporting parameters. History of prior urethral surgery conferred a higher risk of complications and re-intervention. These results can help guide patient selection and counseling.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 8","pages":"1537-1545"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A single-institution experience with the Optilume Urethral Drug Coated Balloon for management of urethral stricture disease. 单一机构使用 Optilume 尿道药物涂层球囊治疗尿道狭窄疾病的经验。
IF 1.9 3区 医学 Q4 ANDROLOGY Pub Date : 2024-08-31 Epub Date: 2024-08-20 DOI: 10.21037/tau-24-104
Ashorne K Mahenthiran, Ramzy T Burns, Mary E Soyster, Morgan Black, Peter J Arnold, Harrison L Love, Matthew J Mellon

Background: Urethral stricture disease is detrimental to quality of life. The Optilume Urethral Drug Coated Balloon (DCB) offers a solution utilizing a paclitaxel-coated balloon to expand strictures and prevent recurrence. Following the ROBUST trials, it has been proposed that DCB is more effective than conventional endoscopic management for recurrent, small anterior urethral strictures. Our study provides insights into practical applications and outcomes using DCB for urethral stricture disease.

Methods: A retrospective review was performed of patients who underwent DCB for urethral strictures at our institution from November 2022 to August 2023 with follow-up evaluated through January 2024. Demographics, stricture characteristics, operative details, and postoperative outcomes were collected. Primary endpoint was need for repeat intervention as determined by symptomatic burden and subsequently postoperative post-void residual if obtained. Secondary endpoint was complication rate. Statistical analysis was conducted using STATA/BE17.0 software to create Kaplan-Meier curves for time to repeat intervention after treatment with DCB.

Results: Of 43 patients, 16 had no prior treatment. The other 27 had endoscopic treatment and of this group, 11 also had additional urethroplasty. Stricture etiologies included 20 iatrogenic, 14 idiopathic, 5 radiation-related, 2 inflammatory, and 2 traumatic. Stricture locations were 2 fossa navicularis, 7 pendulous, 17 bulbar, 7 membranous, 3 prostatic, and 7 bladder neck contractures. Mean balloon dilation lasted 8.4±2.7 minutes. All patients had a minimum follow-up of 150 days postoperatively and the mean duration of follow-up for the cohort was 290.3±87.0 days. The average postoperative post-void residual was 33.4±90.6 milliliters. Two patients had immediate complications: 1 with urinary retention after catheter removal requiring suprapubic tube placement and 1 with urinary tract infection requiring antibiotics. Four patients required repeat interventions: 1 endoscopic dilation, 1 graft urethroplasty, and 2 repeat DCB procedures. Mean time to repeat intervention was 203.5±82.6 days, and no patient required repeat intervention within 145 days of initial surgery.

Conclusions: DCB offers a safe and less invasive treatment for both treatment-naïve and recurrent urethral strictures with paclitaxel coating to prevent recurrence. Repeat intervention was not required for 90.7% of our cohort within an average follow-up duration of 9 months postoperatively. As DCB grows in clinical use, investigation into its long-term efficacy is justified.

背景:尿道狭窄疾病有损生活质量。Optilume 尿道药物涂层球囊(DCB)提供了一种利用紫杉醇涂层球囊扩张狭窄并防止复发的解决方案。在 ROBUST 试验之后,有人提出 DCB 比传统的内窥镜疗法更能有效治疗复发性小前尿道狭窄。我们的研究提供了使用 DCB 治疗尿道狭窄疾病的实际应用和结果:我们对 2022 年 11 月至 2023 年 8 月期间在我院接受 DCB 治疗尿道狭窄的患者进行了回顾性研究,并对 2024 年 1 月之前的随访情况进行了评估。我们收集了患者的人口统计学特征、狭窄特征、手术细节和术后结果。主要终点是根据症状负担和随后获得的术后排尿残余物确定是否需要重复干预。次要终点是并发症发生率。使用 STATA/BE17.0 软件进行统计分析,绘制出 DCB 治疗后重复介入治疗时间的 Kaplan-Meier 曲线:结果:43 名患者中,16 人之前未接受过治疗。结果:在 43 名患者中,16 人之前未接受过治疗,另外 27 人接受过内窥镜治疗,其中 11 人还接受了额外的尿道成形术。尿道狭窄的病因包括 20 例先天性、14 例特发性、5 例辐射相关、2 例炎症性和 2 例外伤性。狭窄部位包括:舟状窝 2 例、下垂 7 例、球部 17 例、膜部 7 例、前列腺 3 例和膀胱颈挛缩 7 例。平均球囊扩张时间为 8.4±2.7 分钟。所有患者的术后随访时间至少为 150 天,平均随访时间为(290.3±87.0)天。术后平均残余量为 33.4±90.6 毫升。两名患者出现了直接并发症:1名患者在拔除导尿管后出现尿潴留,需要放置耻骨上导尿管,1名患者出现尿路感染,需要使用抗生素。四名患者需要重复介入治疗:1 例内窥镜扩张术,1 例移植尿道成形术,2 例重复 DCB 手术。重复干预的平均时间为(203.5±82.6)天,没有患者在首次手术后145天内需要重复干预:结论:DCB是一种安全、创伤较小的治疗方法,适用于治疗无效和复发的尿道狭窄,其紫杉醇涂层可预防复发。在术后平均 9 个月的随访时间内,90.7% 的患者无需再次进行干预。随着 DCB 临床应用的增加,有必要对其长期疗效进行研究。
{"title":"A single-institution experience with the Optilume Urethral Drug Coated Balloon for management of urethral stricture disease.","authors":"Ashorne K Mahenthiran, Ramzy T Burns, Mary E Soyster, Morgan Black, Peter J Arnold, Harrison L Love, Matthew J Mellon","doi":"10.21037/tau-24-104","DOIUrl":"https://doi.org/10.21037/tau-24-104","url":null,"abstract":"<p><strong>Background: </strong>Urethral stricture disease is detrimental to quality of life. The Optilume Urethral Drug Coated Balloon (DCB) offers a solution utilizing a paclitaxel-coated balloon to expand strictures and prevent recurrence. Following the ROBUST trials, it has been proposed that DCB is more effective than conventional endoscopic management for recurrent, small anterior urethral strictures. Our study provides insights into practical applications and outcomes using DCB for urethral stricture disease.</p><p><strong>Methods: </strong>A retrospective review was performed of patients who underwent DCB for urethral strictures at our institution from November 2022 to August 2023 with follow-up evaluated through January 2024. Demographics, stricture characteristics, operative details, and postoperative outcomes were collected. Primary endpoint was need for repeat intervention as determined by symptomatic burden and subsequently postoperative post-void residual if obtained. Secondary endpoint was complication rate. Statistical analysis was conducted using STATA/BE17.0 software to create Kaplan-Meier curves for time to repeat intervention after treatment with DCB.</p><p><strong>Results: </strong>Of 43 patients, 16 had no prior treatment. The other 27 had endoscopic treatment and of this group, 11 also had additional urethroplasty. Stricture etiologies included 20 iatrogenic, 14 idiopathic, 5 radiation-related, 2 inflammatory, and 2 traumatic. Stricture locations were 2 fossa navicularis, 7 pendulous, 17 bulbar, 7 membranous, 3 prostatic, and 7 bladder neck contractures. Mean balloon dilation lasted 8.4±2.7 minutes. All patients had a minimum follow-up of 150 days postoperatively and the mean duration of follow-up for the cohort was 290.3±87.0 days. The average postoperative post-void residual was 33.4±90.6 milliliters. Two patients had immediate complications: 1 with urinary retention after catheter removal requiring suprapubic tube placement and 1 with urinary tract infection requiring antibiotics. Four patients required repeat interventions: 1 endoscopic dilation, 1 graft urethroplasty, and 2 repeat DCB procedures. Mean time to repeat intervention was 203.5±82.6 days, and no patient required repeat intervention within 145 days of initial surgery.</p><p><strong>Conclusions: </strong>DCB offers a safe and less invasive treatment for both treatment-naïve and recurrent urethral strictures with paclitaxel coating to prevent recurrence. Repeat intervention was not required for 90.7% of our cohort within an average follow-up duration of 9 months postoperatively. As DCB grows in clinical use, investigation into its long-term efficacy is justified.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 8","pages":"1498-1505"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial urinary sphincter for neurogenic urinary incontinence: a narrative review. 人工尿道括约肌治疗神经源性尿失禁:综述。
IF 1.9 3区 医学 Q4 ANDROLOGY Pub Date : 2024-08-31 Epub Date: 2023-06-19 DOI: 10.21037/tau-22-794
Bridget L Findlay, Daniel S Elliott

Background and objective: The artificial urinary sphincter (AUS) is most known for its use in the treatment of moderate to severe post-prostatectomy stress urinary incontinence. However, another lesser-known indication includes stress incontinence related to intrinsic sphincter deficiency (ISD) in the neurogenic bladder population. The purpose of this review is to discuss specific technical considerations related to device implantation in this population, efficacy, durability, and complications.

Methods: We performed a non-systematic literature review using the PubMed Database to identify articles specifically related to treatment of neurogenic urinary incontinence using an artificial urinary sphincter.

Key content and findings: More proximal placement of the cuff at the bladder neck is preferred in the neurogenic population due to higher rates of erosion and complications related to frequent clean intermittent catheterization or cystoscopic procedures when placed along the bulbar urethra. Robotic-assisted laparoscopic cuff placement has emerged as a safe and effective alternative to open surgery in select patients. Although continence rates are highly variable due the subjectivity of the term, functional continence (≤1 pad, ± nighttime incontinence) is reported to be between 75-90%. The need for secondary surgery for explanation with or without revision/replacement is higher in neurogenic patients compared to non-neurogenic patients.

Conclusions: Neurogenic urinary incontinence is a complex condition due to the interplay of urethral resistance and bladder function/compliance. While there are a variety of strategies to treat neurogenic incontinence, high quality data from direct comparisons are lacking. Although AUS comes with a high revision rate, functional outcomes for continence with bladder neck placement are promising in this population.

背景和目的:人工尿道括约肌(AUS)因用于治疗中度至重度前列腺切除术后压力性尿失禁而广为人知。然而,另一个鲜为人知的适应症包括与神经源性膀胱人群内在括约肌缺陷(ISD)有关的压力性尿失禁。本综述旨在讨论与该人群设备植入、疗效、耐用性和并发症相关的具体技术注意事项:我们使用 PubMed 数据库进行了一次非系统性文献综述,以确定与使用人工尿道括约肌治疗神经源性尿失禁相关的文章:神经源性尿失禁患者首选在膀胱颈部近端放置人工尿道括约肌,因为沿球部尿道放置人工尿道括约肌时,与频繁清洁间歇性导尿或膀胱镜手术相关的侵蚀和并发症发生率较高。在特定患者中,机器人辅助腹腔镜袖带置入术已成为开腹手术的一种安全有效的替代方法。尽管由于术语的主观性,尿失禁率变化很大,但据报道,功能性尿失禁率(≤1 个尿垫,± 夜间尿失禁)在 75%-90% 之间。与非神经源性尿失禁患者相比,神经源性尿失禁患者需要进行二次手术进行解释,无论是否需要翻修/更换:由于尿道阻力和膀胱功能/顺应性的相互作用,神经源性尿失禁是一种复杂的疾病。虽然治疗神经源性尿失禁的策略多种多样,但缺乏直接比较的高质量数据。虽然 AUS 的翻修率很高,但在这一人群中,膀胱颈置入术的功能性尿失禁疗效很好。
{"title":"Artificial urinary sphincter for neurogenic urinary incontinence: a narrative review.","authors":"Bridget L Findlay, Daniel S Elliott","doi":"10.21037/tau-22-794","DOIUrl":"https://doi.org/10.21037/tau-22-794","url":null,"abstract":"<p><strong>Background and objective: </strong>The artificial urinary sphincter (AUS) is most known for its use in the treatment of moderate to severe post-prostatectomy stress urinary incontinence. However, another lesser-known indication includes stress incontinence related to intrinsic sphincter deficiency (ISD) in the neurogenic bladder population. The purpose of this review is to discuss specific technical considerations related to device implantation in this population, efficacy, durability, and complications.</p><p><strong>Methods: </strong>We performed a non-systematic literature review using the PubMed Database to identify articles specifically related to treatment of neurogenic urinary incontinence using an artificial urinary sphincter.</p><p><strong>Key content and findings: </strong>More proximal placement of the cuff at the bladder neck is preferred in the neurogenic population due to higher rates of erosion and complications related to frequent clean intermittent catheterization or cystoscopic procedures when placed along the bulbar urethra. Robotic-assisted laparoscopic cuff placement has emerged as a safe and effective alternative to open surgery in select patients. Although continence rates are highly variable due the subjectivity of the term, functional continence (≤1 pad, ± nighttime incontinence) is reported to be between 75-90%. The need for secondary surgery for explanation with or without revision/replacement is higher in neurogenic patients compared to non-neurogenic patients.</p><p><strong>Conclusions: </strong>Neurogenic urinary incontinence is a complex condition due to the interplay of urethral resistance and bladder function/compliance. While there are a variety of strategies to treat neurogenic incontinence, high quality data from direct comparisons are lacking. Although AUS comes with a high revision rate, functional outcomes for continence with bladder neck placement are promising in this population.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 8","pages":"1738-1743"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Translational andrology and urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1